125 related articles for article (PubMed ID: 33177018)
1. [Effect of MDR1 and CYP3A5 gene polymorphisms on outcomes of patients receiving imatinib treatment for chronic myeloid leukemia].
He Y; Zao X; Wei X
Nan Fang Yi Ke Da Xue Xue Bao; 2018 Jan; 38(1):34-41. PubMed ID: 33177018
[TBL] [Abstract][Full Text] [Related]
2. Do polymorphisms in MDR1 and CYP3A5 genes influence the risk of cytogenetic relapse in patients with chronic myeloid leukemia on imatinib therapy?
Harivenkatesh N; Kumar L; Bakhshi S; Sharma A; Kabra M; Velpandian T; Gogia A; Shastri SS; Gupta YK
Leuk Lymphoma; 2017 Sep; 58(9):1-9. PubMed ID: 28367681
[TBL] [Abstract][Full Text] [Related]
3. [Relation between single Nucleotide Polymorphisms of CYP3A5 Gene and MDR1 Gene Loci and Risk of CML Cytogenetic Relapse].
Yang ZY; Zhang YS; Liang CX; Zhou ZJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Dec; 26(6):1644-1648. PubMed ID: 30501698
[TBL] [Abstract][Full Text] [Related]
4. Influence of MDR1 and CYP3A5 genetic polymorphisms on trough levels and therapeutic response of imatinib in newly diagnosed patients with chronic myeloid leukemia.
Harivenkatesh N; Kumar L; Bakhshi S; Sharma A; Kabra M; Velpandian T; Gogia A; Shastri SS; Biswas NR; Gupta YK
Pharmacol Res; 2017 Jun; 120():138-145. PubMed ID: 28330783
[TBL] [Abstract][Full Text] [Related]
5. Influence of CYP3A5*3 and ABCB1 C3435T on clinical outcomes and trough plasma concentrations of imatinib in Nigerians with chronic myeloid leukaemia.
Adeagbo BA; Bolaji OO; Olugbade TA; Durosinmi MA; Bolarinwa RA; Masimirembwa C
J Clin Pharm Ther; 2016 Oct; 41(5):546-51. PubMed ID: 27426203
[TBL] [Abstract][Full Text] [Related]
6. Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia.
Ni LN; Li JY; Miao KR; Qiao C; Zhang SJ; Qiu HR; Qian SX
Med Oncol; 2011 Mar; 28(1):265-9. PubMed ID: 20204543
[TBL] [Abstract][Full Text] [Related]
7. C1236T polymorphism in MDR1 gene correlates with therapeutic response to imatinib mesylate in Indian patients with chronic myeloid leukaemia.
Chhikara S; Sazawal S; Mishra P; Chaubey R; Mahapatra M; Saxena R
Natl Med J India; 2015; 28(6):272-5. PubMed ID: 27294449
[TBL] [Abstract][Full Text] [Related]
8. Association of MDR1 gene polymorphism (G2677T) with imatinib response in Egyptian chronic myeloid leukemia patients.
Elghannam DM; Ibrahim L; Ebrahim MA; Azmy E; Hakem H
Hematology; 2014 Apr; 19(3):123-8. PubMed ID: 23683876
[TBL] [Abstract][Full Text] [Related]
9.
Louati N; Turki F; Mnif H; Frikha R
J Oncol Pharm Pract; 2022 Jan; 28(1):39-48. PubMed ID: 33565361
[TBL] [Abstract][Full Text] [Related]
10. [Correlation between MDR1 genetic polymorphism and prognosis in acute myeloid leukemia].
Wang D; Ke XY; Wang J; Xu F; Hu YF
Zhonghua Yi Xue Za Zhi; 2007 May; 87(20):1384-8. PubMed ID: 17785057
[TBL] [Abstract][Full Text] [Related]
11. MDR1/ABCB1 gene polymorphisms in patients with chronic myeloid leukemia.
Lardo M; Castro M; Moiraghi B; Rojas F; Borda N; Rey JA; Lazarowski A
Blood Res; 2015 Sep; 50(3):154-9. PubMed ID: 26457282
[TBL] [Abstract][Full Text] [Related]
12. MDR1 gene polymorphism correlated with pathological characteristics and prognosis in patients with primary hepatocellular carcinoma receiving interventional therapy.
Hu W; Huang S; Dong L; Yu C; Li C; Zhang J
Anticancer Drugs; 2019 Mar; 30(3):233-240. PubMed ID: 30779721
[TBL] [Abstract][Full Text] [Related]
13. Melding Pharmacogenomic Effect of
Prasad N; Jaiswal A; Behera MR; Agarwal V; Kushwaha R; Bhadauria D; Kaul A; Gupta A
Kidney Int Rep; 2020 Jan; 5(1):28-38. PubMed ID: 31922058
[TBL] [Abstract][Full Text] [Related]
14. Do SLCO1B3 (T334G) and CYP3A5*3 polymorphisms affect response in Egyptian chronic myeloid leukemia patients receiving imatinib therapy?
Bedewy AM; El-Maghraby SM
Hematology; 2013 Jul; 18(4):211-6. PubMed ID: 23394475
[TBL] [Abstract][Full Text] [Related]
15. Association of C3435T, C1236T and C4125A Polymorphisms of the MDR-1 Gene in Egyptian Children with Acute Lymphoblastic Leukaemia.
Talaat RM; Y K El-Kelliny M; El-Akhras BA; Bakry RM; Riad KF; Guirgis AA
Asian Pac J Cancer Prev; 2018 Sep; 19(9):2535-2543. PubMed ID: 30256048
[TBL] [Abstract][Full Text] [Related]
16. Multi-drug resistance-1 gene polymorphisms in nephrotic syndrome: impact on susceptibility and response to steroids.
Youssef DM; Attia TA; El-Shal AS; Abduelometty FA
Gene; 2013 Nov; 530(2):201-7. PubMed ID: 23994685
[TBL] [Abstract][Full Text] [Related]
17. MDR1 polymorphisms have an impact on the prognosis of Chinese diffuse large B cell lymphoma patients.
Ni Y; Yin G; Xiao Z; Fan L; Wang L; Wu Y; Wu H; Qian S; Xu W; Li J; Miao K; Qiu H
Tumour Biol; 2016 Jan; 37(1):1237-44. PubMed ID: 26286835
[TBL] [Abstract][Full Text] [Related]
18. Concurrent effects of ABCB1 C3435T, ABCG2 C421A, and XRCC1 Arg194Trp genetic polymorphisms with risk of cancer, clinical output, and response to treatment with imatinib mesylate in patients with chronic myeloid leukemia.
Salimizand H; Amini S; Abdi M; Ghaderi B; Azadi NA
Tumour Biol; 2016 Jan; 37(1):791-8. PubMed ID: 26250462
[TBL] [Abstract][Full Text] [Related]
19. A variant 2677A allele of the MDR1 gene affects fexofenadine disposition.
Yi SY; Hong KS; Lim HS; Chung JY; Oh DS; Kim JR; Jung HR; Cho JY; Yu KS; Jang IJ; Shin SG
Clin Pharmacol Ther; 2004 Nov; 76(5):418-27. PubMed ID: 15536457
[TBL] [Abstract][Full Text] [Related]
20. Molecular study of ABCB1 gene and its correlation with imatinib response in chronic myeloid leukemia.
Ben Hassine I; Gharbi H; Soltani I; Ben Hadj Othman H; Farrah A; Amouri H; Teber M; Ghedira H; Ben Youssef Y; Safra I; Abbes S; Menif S
Cancer Chemother Pharmacol; 2017 Oct; 80(4):829-839. PubMed ID: 28836054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
